


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
NEW INDICATION FOR BENMELSTOBART IN COMBINATION WITH
ANLOTINIB FOR THE TREATMENT OF
ALVEOLAR SOFT PART SARCOMA APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Benmelstobart (trade name: 安得衛®) in combination with Anlotinib (trade name: FOCUS V®), has received approval for marketing from the National Medical Products Administration (NMPA) of China for the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). Benmelstobart and Anlotinib are category 1 innovative drugs independently developed by the Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”). This marks the fourth approved indication for this combination therapy, following prior approvals in China for the treatment of first-line small cell lung cancer, second-line or later endometrial cancer, and first-line renal cell carcinoma.

Benmelstobart is an innovative humanised anti-PD-L1 monoclonal antibody with a novel sequence; this marks its fifth approved indication. Anlotinib is a novel, orally administered, multi-targeted small-molecule tyrosine kinase inhibitor (TKI); this marks its eleventh approved indication.

This approval is supported by robust data from the TQB2450-Ib-02 clinical study. The results showed that the primary endpoint, objective response rate (ORR), reached 72.41%, with 10.34% of subjects achieving complete response (CR) as their best response. Prior chemotherapy history had no significant impact on ORR, and no new safety signals were observed. With a median follow-up of 24.9 months, the median progression-free survival (PFS) had not yet been reached.

ASPS is a rare, highly metastatic soft tissue malignancy with a poor prognosis, commonly occurring in adolescents, accounting for approximately 0.5%-1.0%^[1] of soft tissue sarcomas. However, ASPS is not sensitive to radiotherapy or chemotherapy, and radiotherapy is often ineffective in controlling tumour growth and metastasis. There are limited treatment options, with a recurrence rate as high as 70% and a 5-year overall survival rate of only 20%-46%^[2-3].

Anlotinib has received a Grade I recommendation (Class 2A evidence) in the *Chinese Society of Clinical Oncology (CSCO): Guidelines for the Diagnosis and Treatment of Bone and Soft Tissue Tumours (2024 Edition)* for the first-line treatment of advanced ASPS. On this basis, the successful approval of Benmelstobart in combination with Anlotinib will provide a new treatment option for these patients.

Sources:

- [1] Yuan X, Zhou B, Zhong J. Prognostic factors of alveolar soft part sarcoma in children and adolescents: a populationbased study[J]. *J Stomatol Oral Maxillofac Surg*, 2024,125(3S):101852.
- [2] Chen AP, Sharon E, O'Sullivan-Coyne G, et al. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. *N Engl J Med*. 2023, 389(10): 911-921.
- [3] Qiao Li, Liu Jinfeng, Wang Bo, et al. Advances in Targeted and Immunotherapy for Alveolar Soft Part Sarcoma [J]. *Journal of Shandong Medical College*, 2025, 47(02): 25-27.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 20 April 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.